Digital health startup Hinge Health saw a 17% IPO pop on its first day of trading on the New York Stock Exchange, closing the day at $37.56 a share.
Hinge Health and its selling shareholders raised $437 million in the IPO, which priced shares at $32 each for a fully diluted market cap of about $3.5 billion.
The debut is a long-awaited windfall for early investors Atomico, 11.2 Capital and Insight Partners, and the first major public listing of a VC-backed healthtech company since 2021.
But the valuation is sobering for its later investors, another reminder that public markets are still valuing tech stocks at a discount from 2021 highs.
Hinge Health’s last two private financings, in January and October 2021, valued the company at $3 billion and $6.2 billion, respectively. Coatue and Tiger Global led both rounds.
Hinge Health stockholders, including Tiger Global and Insight, sold about 5.14 million shares in the IPO.
In Hinge Health’s public listing, most of the investor-held shares will convert to common stock, but in an unusual move, Tiger elected not to convert some of its preferred shares from the Series E round, the company noted in its filings.
Hinge Health’s current financial position is strong despite the valuation reset from its 2021 heyday: Its first quarter revenue grew 50% to $123 million, up from $82 million in Q1 of 2024. It’s also narrowed its losses substantially, from $108 million in 2023 to $11.9 million last year.
Hinge Health offers virtual physical therapy to people with musculoskeletal conditions, a demographic that comprises approximately 40% of US adults. As far as digital health goes, Hinge Health’s product-market fit is strong: Its client base spans 49% of Fortune 500 companies, and its gross margin in Q4 was 82%.
The optimistic pricing and first-day performance may offer a push for other healthtech startups waiting in the wings to IPO, after unexpectedly shaky markets dampened IPO sentiments.
Featured image by Hinge Health
Learn about our editorial standards.